27611 Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)

2021 ◽  
Vol 85 (3) ◽  
pp. AB156
Author(s):  
Linda Stein Gold ◽  
Edward Lain ◽  
Jerry Bagel ◽  
Abby Jacobson
Keyword(s):  
Quality Of Life ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Plaque Psoriasis ◽  
Fixed Combination ◽  
Poor Quality

scholarly journals Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis

2020 ◽  
Vol 4 (6) ◽  
pp. s72
Author(s):  
Alan Menter ◽  
Andrew Blauvelt ◽  
Bruce Strober ◽  
Matthew Colombo ◽  
Renata Kisa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Tyrosine Kinase ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Tyrosine Kinase 2

Abstract not available.

scholarly journals Impact of Vitiligo on Quality of Life: A Cross-sectional Pilot Study from Western India

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Vasudha Abhijit Belgaumkar ◽  
Ravindranath Brahmadeo Chavan ◽  
Nitika S Deshmukh ◽  
Nupur Vasudeo Warke
Keyword(s):  
Quality Of Life ◽  
Surface Area ◽  
Correlation Coefficient ◽  
Body Surface Area ◽  
Body Surface ◽  
Western India ◽  
Care Hospital ◽  
Cross Sectional ◽  
The Impact

Background: Vitiligo is a common, acquired, mucocutaneous discoloration characterized by well-circumscribed depigmented macules. It has profound potential for cosmetic disfigurement and social stigma, which is an often neglected aspect of the disease. Objectives: To analyze the impact of vitiligo on the quality of life (Qol) of patients in western India and To determine the contributory factors. Methods: A cross-sectional, observational study was conducted at a tertiary care hospital on 60 patients with vitiligo (were enrolled after informed consent and ethical approval). Basic patient-related (age, gender, socioeconomic status, co-morbidities) and vitiligo-related variables (body surface area involved, stability, duration of disease, treatment modality) were noted. This information were collated with QoL using a standardized questionnaire, the Dermatology Life Quality Index (DLQI). Statistical analysis was performed using Spearman’s rank correlation coefficient, Pearson’s r, unpaired t-test (SPSS version 16). Results: Mean DLQI score of the study sample was 3.15 ± 4.2 (small effect on QoL). The mean DLQI score in females (3.97) was significantly higher than in males (1.92) (P = 0.046). Also, the DLQI demonstrated a significant positive correlation with body surface area involvement (Spearman’s correlation coefficient = 0.306) (P = 0.018). Other factors were not found to affect the DLQI. Conclusions: Various modifiable and non-modifiable factors influence the QoL of vitiligo patients. Gender- associated stigma may be alleviated by counseling and creating awareness, while the body surface area involvement may be addressed by instituting and appropriate treatment. The clinician must be vigilant for any subtle signs of impairment of QoL to enable timely intervention.

scholarly journals P14 Reducing medication errors using prescribing nudges: intravenous aciclovir on paediatric intensive care

2020 ◽  
Vol 105 (9) ◽  
pp. e13.1-e13
Author(s):  
Jenny Gray ◽  
Nicholas Jones ◽  
Olivia Fuller ◽  
Andrew Schia
Keyword(s):  
Intensive Care ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Error Rate ◽  
Paediatric Intensive Care ◽  
Electronic Prescribing ◽  
Second Phase ◽  
Quality Of Prescribing

AimThis Quality Improvement project is the second phase of a long term project to improve the quality of prescribing on the paediatric intensive care unit (PICU). Small adjustments are made to the electronic prescribing (EP) system, known as ‘nudges’, with the aim of improving the quality of prescribing in terms of error rate or user experience.1 2Intravenous aciclovir is prescribed to most patients admitted to the PICU with suspected meningitis/encephalitis. There is a complicated dosing schedule where the prescriber must decide whether to use body surface area (BSA) or weight to calculate the required dose. Underdosing risks subtherapeutic treatment of a viral encephalitis and overdosing risks acute kidney injury. Within our EP system, dosing by weight can be automated, but dosing by BSA cannot.A project in 2018 used a ‘nudge’ to alter the order of prescribing options in the drop down menu on the EP system. This reduced the error rate from 26% to 17% by reducing the likelihood of picking the wrong indication for acyclovir.3 However, a re-audit in October to December 2018 found the error rate had crept back up to 32%. Prescribing on the EP system is a multi-step process. Prescribers had to pick ‘aciclovir’ to choose the weight based dose or ‘aciclovir injection 3 month-11 yr‘ to choose the BSA based dosing. When ‘aciclovir’ was picked, this removed the body surface area dosing option from the prescriber’s screen and led them in the direction of an incorrect dose.MethodThe intervention for this project was to amalgamate all weight and BSA dosing options for acyclovir within the EP system, and then order them by age so that the prescriber could see all options simultaneously. This change was designed and implemented by our electronic prescribing support pharmacist in April 2019. Pre and post change prescriptions were audited by pharmacy undergraduate students for accuracy using data downloaded from the EP system.ResultsThe error rate post change was 8% (pre change 32%). The remaining errors reflect transcribing of an incorrect dose initiated outside of the PICU from a referring ward or hospital.ConclusionThis project shows that small, ‘smart’ changes within EP configuration can improve the quality of prescribing.Future work involves working with the software company to incorporate the ability to automatically calculate the dose based on BSA, further reducing the need for manual calculations. This project would not have been possible without the skills and knowledge of our electronic prescribing support pharmacy team.ReferencesPatel MS, et al. Nudge units to improve the delivery of health care. NEJM 2018; 378: 214–216Cafazzo JA, et al. From discovery to design: the evolution of human factors in healthcare. healthcare quarterly 2012; 15: 24–29Gunning C, Gray J. Audit of acyclovir prescribing to assess whether changing the order of drop down box options in an electronic prescribing system can reduce prescribing errors. Archives of Disease in Childhood 2019; 104:7

The distance from the Amplatzer septal occluder to the mitral valve in patients undergoing interventional closure of defects in the oval fossa increases with growth of the patient

2004 ◽  
Vol 14 (5) ◽  
pp. 494-497 ◽  
Author(s):  
Robert F. English ◽  
Jose A. Ettedgui
Keyword(s):  
Mitral Valve ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Left Atrial ◽  
Left Ventricular ◽  
Amplatzer Septal Occluder ◽  
Operative Closure

The Amplatzer septal occluder is an alternative to operative closure of atrial septal defects within the oval fossa. An issue when deploying the device is its distance from the mitral valve. The purpose of this study is to determine how this distance changes with growth of the patient. We identified, through a review of charts, all patients undergoing closure of defects within the oval fossa by insertion of an Amplatzer septal occluder. Data were obtained from the echocardiogram 24 hours after closure, and at most recent follow-up, including left ventricular end-diastolic diameter, left atrial diameter, degree of mitral valvar regurgitation, body surface area, and distance from the device to the mitral valve. We divided the patients into 2 groups based upon change in body surface area. The first group had an increase in body surface area of at least 10%. All others were in the second group.We inserted 55 Amplatzer septal occluders in 54 patients. Of these we excluded 17 patients, 1 because quality of images was inadequate, 1 who underwent placement of 2 devices, 1 in whom the device embolised to the left ventricle the day after deployment, and 14 who have not yet had a follow-up echocardiogram.The group which exhibited an increase in body surface area of greater than 10% demonstrated an increase in distance from the device to the mitral valve, left ventricular end-diastolic, and left atrial diameters. Those who did not undergo significant growth had no increase in distance from the device to the mitral valve, but did have an increase in left atrial and left ventricular end-diastolic diameters. No patient developed mitral regurgitation. We conclude that, when deploying an Amplatzer septal occluder close to the mitral valve in children, the distance from the device to the mitral valve can be expected to increase with growth of the patient.

Tildrakizumab Shows Significant Efficacy in Psoriasis Treatment With Comorbid Immunoglobulin A Nephropathy: A Case Report

2020 ◽  
Vol 5 (4) ◽  
pp. 160-163
Author(s):  
Eingun James Song
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Plaque Psoriasis ◽  
Global Assessment ◽  
Immunoglobulin A ◽  
Immunoglobulin A Nephropathy ◽  
Severe Plaque Psoriasis

Background: Chronic kidney disease is a relative contraindication for conventional systemic therapy in patients with psoriasis. Although biologic agents may be suitable in these patients due to their elimination via endogenous metabolism and protein degradation, no dedicated studies have evaluated the safety of biologics in patients with psoriasis and chronic kidney disease. Tildrakizumab—an anti-interleukin-23p19 monoclonal antibody—is approved for treatment of moderate-to-severe plaque psoriasis. Objective: To evaluate efficacy and safety of tildrakizumab in a 56-year-old woman with moderate-to-severe plaque psoriasis and comorbid immunoglobulin A nephropathy. Methods: Subcutaneous tildrakizumab 100 mg was administered at weeks 0, 4, 20, 33, and 48. Assessments included body surface area affected, physician’s global assessment score, and laboratory assessments. Results: At initial presentation, patient had predominantly plaque-type psoriasis involving 5% body surface area with a static physician’s global assessment score of 3. Patient failed an adequate trial of ultrapotent topical steroids. Baseline laboratory tests confirmed renal impairment with blood creatinine level of 2.0 mg/dL and an estimated glomerular filtration rate of 27.0 mL/min/1.73 m2. Administration of subcutaneous tildrakizumab 100 mg led to near-complete skin clearance by week 33, with a durable response to week 48. No treatment-related adverse events were reported through 48 weeks. Metabolic and hematological parameters remained grossly unchanged. Conclusion: Tildrakizumab was well tolerated and effective for treatment of moderate-to-severe plaque psoriasis in a patient with comorbid immunoglobulin A nephropathy.

Sign in / Sign up

Export Citation Format

Share Document